Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
Phase 3
Completed
- Conditions
- B-cell Non Hodgkin's Lymphoma
- Interventions
- Registration Number
- NCT02787239
- Lead Sponsor
- Shanghai Henlius Biotech
- Brief Summary
Multicenter, Randomized, Double-blind, Parallel, Phase III Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and MabThera in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 407
Inclusion Criteria
- Untreated CD20-positive DLBCL confirmed.
- IPI score of 1 to 2, Stage I ~ IV, Score 0 needs to accompanied by bulky disease, which is defined as the presence of a tumor mass with a diameter of more than 7.5 cm.
- ECOG performance status of 0 to 2.
- More than 6 months life expectancy.
- At least one measurable lesion: For nodal tumor mass, more than 1.5 cm in the long axis and more than 1.0 cm in the short axis; For extranodal tumor mass, more than 1.0 cm in the long axis.
- 18 years to 70 years; Male or female patients.
Exclusion Criteria
- Known allergic reactions against human or murine monoclonal antibody, murine products, or foreign proteins.
- Known allergic reactions against any component of CHOP regimen.
- Previous treatment for NHL, including chemotherapy, immunotherapy, partial radiotherapy for lymphoma, monoclonal antibody therapy or surgical treatment (excluding lymph node biopsies and surgical resection for non-lymphoma lesions).
- History of cytotoxic drugs treatment or anti-CD20 monoclonal antibody treatment for other disease (e.g., rheumatoid arthritis).
- Prior use of any monoclonal antibody within 3 months.
- Primary central nervous system(CNS) lymphoma, secondary CNS involvement, grey zone lymphoma (GZL) between burkitt and DLBCL, primary effusion lymphoma, plasmablastic lymphoma, primary cutaneous DLBCL, anaplastic lymphoma kinase(ALK) positive DLBCL or transformed lymphoma.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description HLX01 CHOP 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks) HLX01 HLX01 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks) Rituximab Rituximab 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks) Rituximab CHOP 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
- Primary Outcome Measures
Name Time Method Percentage of Participants With Overall Response Rate (ORR) 18 weeks
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of HLX01 in CD20+ DLBCL compared to MabThera?
How does the efficacy of HLX01-CHOP compare to standard Rituximab-CHOP in untreated CD20+ DLBCL patients?
Which biomarkers correlate with response to HLX01 biosimilar in B-cell NHL clinical trials?
What adverse events are associated with HLX01 biosimilar in phase III lymphoma studies?
How does HLX01 compare to other rituximab biosimilars in CD20+ DLBCL treatment outcomes?
Trial Locations
- Locations (1)
Cancer Hospital, Chinese Academy of Medical Sciences
🇨🇳Beijing, China
Cancer Hospital, Chinese Academy of Medical Sciences🇨🇳Beijing, China